window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Clinical & Regulatory

  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development

    Myomaker Bio launches lab-grown human muscle platform for preclinical drug testing

    Myomaker Bio, a UK biotechnology company spun out from Loughborough [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Opinion & Events,Therapeutic Areas

    Abivax to present nine obefazimod studies at DDW as Phase 3 ulcerative colitis data build

    Abivax will present nine scientific abstracts on obefazimod at Digestive [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Medical devices

    Viz.ai, Johnson & Johnson strike US chronic subdural hematoma AI deal

    Viz.ai has entered a collaboration with Johnson & Johnson to [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development

    Veristat acquires Certara regulatory and medical writing business

    Veristat has agreed to acquire Certara’s regulatory and medical writing [...]

    May 5, 2026
  • Clinical & Regulatory,Manufacturing & Supply Chain,Medical devices

    Trelleborg gains ISO certification for Costa Rica medtech plant

    Trelleborg Medical Solutions has secured ISO 13485:2016 certification for its [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Alto starts Phase 2b ALTO-207 trial in treatment-resistant depression

    Alto Neuroscience has started a Phase 2b trial of ALTO-207 [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ARTCLINE completes enrolment in septic shock trial for ARTICE therapy

    ARTCLINE has completed patient enrolment in a 142-patient randomized study [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline

    Neomorph has closed a $100 million Series B financing to [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    NICE expands Lokelma access for hyperkalaemia after draft recommendation

    The National Institute for Health and Care Excellence (NICE) has [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Emalex wins US patent for ecopipam ODT as Tourette access program grows

    Emalex has secured a US patent for an orally disintegrating [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • NETRIS Pharma Nature publishes pancreatic cancer Phase 1b data showing NP137 survival and surgery gains
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Therapeutic Areas
  • Myomaker Bio launches lab-grown human muscle platform for preclinical drug testing
    Categories: Advanced Therapies, Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development
  • Abivax to present nine obefazimod studies at DDW as Phase 3 ulcerative colitis data build
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Opinion & Events, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top